arrow
S

Shaoyan Hu

Children's Hospital of Soochow University
H指数:22
被引数:1,534

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low-Dose Cytarabine Plus G-CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study

低剂量阿糖胞苷联合G-CSF诱导治疗儿童M2型急性髓系白血病:一项多中心研究

2026-10-010
OAAI
Induction-phase blood arsenic concentration and relapse risk in pediatric acute promyelocytic leukemia treated with arsenic and all-trans retinoic acid

诱导期血液砷浓度与接受砷和全反式维甲酸治疗的儿童急性早幼粒细胞白血病的复发风险

Leukemia
IF13.4
2026-07-230
PRE
High proportion of peripheral blood and haploidentical stem cell transplantation in Chinese children: a nationwide CCBMTR analysis

中国儿童外周血和半相合干细胞移植比例高:一项全国CCBMTR分析

2026-05-120
PRE
Long-Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG-HLH-2018): A Multicenter, Single-Arm Clinical Study

基于依托泊苷和糖皮质激素的分层治疗方案的长期疗效:儿童噬血细胞性淋巴组织细胞增生症(CCHG-HLH-2018)的多中心、单臂临床研究

2025-12-010
PRE
RISK-ADAPTED THERAPY FOR JUVENILE MYELOMONOCYTIC LEUKEMIA: A MULTICENTER, PROSPECTIVE STUDY IN CHINA
2025-11-010
OAAI
Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study

儿童APL中DIC的危险因素:来自CCLG-APL 2016研究的见解

2025-10-230
PRE
Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B-cases report

一线疗法联合鞘内注射地塞米松可有效缓解接受pCAR-19B治疗的复发性儿童B-ALL患者的免疫效应细胞相关神经毒性综合征——病例报告

2025-10-020
OAAI
Haploidentical hematopoietic cell transplantation combined with umbilical cord blood vs. haploidentical hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia patients: a multicenter real-world study

haploidentical hematopoietic cell transplantation combined with umbilical cord blood 与 haploidentical hematopoietic cell transplantation 在 T-cell acute lymphoblastic leukemia 患者中的比较:一项多中心真实世界研究

2025-08-180
PRE
Outcomes of Children and Adolescents with Acute Myeloid Leukemia and KIT Mutations Treated with Low- or Standard-Dose Chemotherapy Plus Dasatinib on the CALSIII-AML18 Trial

CALSIII-AML18试验中,携带KIT突变且接受低剂量或标准剂量化疗联合达沙替尼治疗的儿童和青少年急性髓系白血病患者的结局

BLOOD
IF23.1
2024-11-050
PRE